BidaskClub downgraded shares of Impax Laboratories (NASDAQ:IPXL) from a hold rating to a sell rating in a research report released on Friday.

A number of other research firms have also weighed in on IPXL. Canaccord Genuity set a $19.00 price objective on shares of Impax Laboratories and gave the company a hold rating in a research note on Monday, December 18th. Guggenheim started coverage on shares of Impax Laboratories in a report on Tuesday, December 12th. They set a neutral rating and a $18.00 price target on the stock. Cantor Fitzgerald set a $25.00 price target on shares of Impax Laboratories and gave the company a buy rating in a report on Tuesday, October 17th. Zacks Investment Research raised shares of Impax Laboratories from a hold rating to a buy rating and set a $23.00 price target on the stock in a report on Monday, October 16th. Finally, Royal Bank of Canada set a $17.00 price target on shares of Impax Laboratories and gave the company a hold rating in a report on Tuesday, October 17th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $19.62.

Shares of Impax Laboratories (NASDAQ IPXL) opened at $19.15 on Friday. The firm has a market cap of $1,420.00, a PE ratio of -3.06, a price-to-earnings-growth ratio of 0.96 and a beta of 1.11. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.32 and a current ratio of 1.81. Impax Laboratories has a 12 month low of $7.75 and a 12 month high of $25.70.

Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.03. The business had revenue of $206.40 million during the quarter, compared to analyst estimates of $208.38 million. Impax Laboratories had a negative net margin of 56.59% and a positive return on equity of 9.06%. Impax Laboratories’s revenue was down 9.4% compared to the same quarter last year. During the same period last year, the business earned $0.37 EPS. equities research analysts predict that Impax Laboratories will post 0.64 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio boosted its holdings in shares of Impax Laboratories by 12.7% in the second quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock worth $111,000 after buying an additional 780 shares during the last quarter. TIAA CREF Investment Management LLC lifted its holdings in Impax Laboratories by 1.0% during the second quarter. TIAA CREF Investment Management LLC now owns 238,473 shares of the specialty pharmaceutical company’s stock valued at $3,839,000 after purchasing an additional 2,463 shares in the last quarter. Voya Investment Management LLC lifted its holdings in Impax Laboratories by 7.9% during the second quarter. Voya Investment Management LLC now owns 33,947 shares of the specialty pharmaceutical company’s stock valued at $547,000 after purchasing an additional 2,499 shares in the last quarter. California Public Employees Retirement System lifted its holdings in Impax Laboratories by 2.2% during the second quarter. California Public Employees Retirement System now owns 114,900 shares of the specialty pharmaceutical company’s stock valued at $1,850,000 after purchasing an additional 2,500 shares in the last quarter. Finally, American International Group Inc. lifted its holdings in Impax Laboratories by 5.9% during the third quarter. American International Group Inc. now owns 58,242 shares of the specialty pharmaceutical company’s stock valued at $1,182,000 after purchasing an additional 3,233 shares in the last quarter. 91.54% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “BidaskClub Lowers Impax Laboratories (IPXL) to Sell” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/02/06/bidaskclub-lowers-impax-laboratories-ipxl-to-sell.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.